MedTrace Logo

Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel in Advanced Ovarian Cancer

NCT02681432 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-08-21

No results posted yet for this study

Summary

Randomized clinical trial to asses the efficacy of closed abdomen hyperthermia intraperitoneal chemotherapy with paclitaxel in ovarian cancer.

Conditions

  • Epithelial Ovarian Cancer

Interventions

DRUG

HIPEC

Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Paclitaxel (175 mg/m2) for 60 minutes at 42-43 degrees.

PROCEDURE

No HIPEC

Cytoreductive surgery without HIPEC

Sponsors & Collaborators

  • Hospital General de Ciudad Real

    collaborator OTHER

  • University of Castilla-La Mancha

    collaborator OTHER

  • PEDRO VILLAREJO CAMPOS

    lead OTHER

Principal Investigators

  • Pedro Villarejo Campos, MD, PhD · SESCAM

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2019-09-30
Completion
2019-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02681432 on ClinicalTrials.gov